Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study

Secondary hyperparathyroidism (SHPT) is a serious complication that increases the risk of bone disorders in patients with chronic kidney disease (CKD) undergoing hemodialysis. Etelcalcetide is the first injectable calcimimetic approved for treatment of SHPT, which reduces bone turnover markers and s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical therapeutics 2018-12, Vol.40 (12), p.2099-2111
Hauptverfasser:	Shigematsu, Takashi, Fukagawa, Masafumi, Yokoyama, Keitaro, Akiba, Takashi, Fujii, Akifumi, Odani, Motoi, Akizawa, Tadao
Format:	Artikel
Sprache:	eng
Schlagworte:	Acid phosphatase Acid phosphatase (tartrate-resistant) Acid resistance Alkaline phosphatase Bone diseases Bone turnover calcimimetic Calcium Calcium phosphates Cardiovascular disease Correlation analysis Data processing Dialysis Enzymes etelcalcetide Fibroblast growth factor 23 Fibroblasts Growth factors Hemodialysis Hyperparathyroidism Immunoassay Intravenous administration Kidney diseases Males Multivariate analysis Parathyroid Parathyroid hormone Patients Phosphatase Phosphate Phosphates Reduction secondary hyperparathyroidism Serum levels Two dimensional models Vitamin D
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!